Natera Inc., the US-based genetic testing company, has seen its co-founder Sheena Jonathan offload a significant block of shares, with the transaction valued at approximately $836,898 (£650,000). The sale was recorded in a filing with the Securities and Exchange Commission (SEC) on 15 July 2026, and comes amid broader insider trading activity at the firm.
Jonathan, who co-founded the company in 2003, has not publicly commented on the reasons behind the sale. The transaction was executed under a pre-arranged trading plan, known as a Rule 10b5-1 plan, which allows company insiders to sell shares at predetermined times to avoid accusations of trading on non-public information. Such plans are common among executives and founders.
Natera, headquartered in Austin, Texas, is best known for its non-invasive prenatal testing (NIPT) and liquid biopsy tests for cancer detection. The company has seen volatile share price movements over the past year, influenced by regulatory developments, reimbursement changes in the US healthcare system, and competition in the genomics sector.
For UK investors, the sale serves as a reminder of the importance of monitoring insider transactions, particularly in growth-stage biotech firms that form part of global portfolios. While insider sales do not necessarily indicate a lack of confidence—they can be driven by tax planning, diversification, or personal liquidity needs—they are closely watched by market analysts for potential signals about a company's near-term outlook.
Analysts at brokerages covering Natera have noted that the company's fundamentals remain tied to its ability to secure broad insurance coverage for its tests and expand its oncology pipeline. The stock's performance is also sensitive to FDA approval cycles and clinical trial results, which continue to be key catalysts for the broader genetic testing industry.